Roche Palo Alto LLC

Joshua Paul Gergely Taygerly

Zachary Kevin Sweeney

Yan Lou

Timothy D Owens

Jim W Li

Javier De Vicente Fidalgo

Francisco Xavier Talamas

Michael Soth

Ryan Craig Schoenfeld

Rama K Kondru

Joel McIntosh

Joshua Kennedy-Smith

Matthew C Lucas

Fariborz Firooznia

Nolan James Dewdney

Keshab Sarma

Bradley E Loe

Daniel Fishlock

Bradley E Loc

Steven Berthel

Jun-Bae Hong

Method for treating an HCV infection and inhibiting HCV replication with a compound of formula I wherein R, R, R, R, X, X, Xand Xand as defined herein 

Quinoline inhibitors of hepatitis C virus polymerase

Compounds having the formula I wherein wherein R, Rand Rare as defined herein are Hepatitis C virus NS5b polymerase inhibitors with improved bioavailability. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

Heterocyclic antiviral compounds

This application discloses 5-phenyl-1H-pyridin-2-one, 6-phenyl-2H-pyridazin-3-one, and 5-Phenyl-1H-pyrazin-2-one derivatives according to generic Formula I-III: wherein, variables Q, R, X, X', Y, Y, Y, Y, Y, Y, m, and n are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I-III and at least one carrier, diluent or excipient.

Inhibitors of Bruton's tyrosine kinase

Compounds having the formula I wherein wherein R, R, R, R, X, X, Xand Xand as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.

Quinoline inhibitors of HCV polymerase

This application discloses 5-phenyl-1H-pyridin-2-one and 6-phenyl-2H-pyridazin-3-one derivatives according to generic Formulae I-III: wherein, variables R, X, Y, Y, Y, Y, n and m are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formulae I-III and at least one carrier, diluent or excipient.

Inhibitors of bruton's tyrosine kinase

Growing community of inventors

San Francisco, CA, United States of America

Joshua Paul Gergely Taygerly